Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
ArsenalBio has successfully raised $325 million in a Series C financing round, marking one of the largest biotech funding rounds of the year. This investment will support the company's ongoing development efforts and scale its manufacturing capabilities for T-cell medicines. The funding round ranks as the fourth largest biotech raise of 2024, following Xaira Therapeutics' $1 billion, Mirador Therapeutics' $400 million, and Formation Bio's $372 million. ArsenalBio expressed gratitude to both new and existing investors for their support.
How do you calculate a biotech IPO? You start at the end and work backwards and it becomes clear. Congrats to ArsenalBio, one of our Endpoints 11 alumni. Raised $325M https://t.co/Vb2lr3lvM2
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds https://t.co/xCYSvUaFgL by @gwendolynawu
We are excited to announce our $325 million #SeriesC financing. This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines. We thank the new investors along with our existing investors for their… https://t.co/AIdJ2sJ1RR